Completed Phase II clinical trials demonstrated that T2D patients treated with Fasiglifam had reduced blood glucose levels, increased insulin levels, and resulted in a 1.2–1.4% reduction in hemoglobin A1c (HbA1c) levels (32–36) (Table 1). Here, INS is linked to type 2 diabetes mellitus.